Yunnan Jianzhijia Health-Chain Co Ltd
Jianzhijia Pharmaceutical Chain Group Co., Ltd. engages in the pharmaceutical retail business in China. The company offers pharmaceuticals, health foods, personal care products, household health products, convenience foods, and daily consumables through offline community professional pharmacies, convenience stores, community clinics, Chinese medicine clinics, and physical examination centers in b… Read more
Yunnan Jianzhijia Health-Chain Co Ltd (605266) - Net Assets
Latest net assets as of September 2025: CN¥2.62 Billion CNY
Based on the latest financial reports, Yunnan Jianzhijia Health-Chain Co Ltd (605266) has net assets worth CN¥2.62 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥9.74 Billion) and total liabilities (CN¥7.11 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.62 Billion |
| % of Total Assets | 26.95% |
| Annual Growth Rate | 33.86% |
| 5-Year Change | 63.4% |
| 10-Year Change | 1456.93% |
| Growth Volatility | 52.91 |
Yunnan Jianzhijia Health-Chain Co Ltd - Net Assets Trend (2014–2024)
This chart illustrates how Yunnan Jianzhijia Health-Chain Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Yunnan Jianzhijia Health-Chain Co Ltd (2014–2024)
The table below shows the annual net assets of Yunnan Jianzhijia Health-Chain Co Ltd from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.78 Billion | -2.25% |
| 2023-12-31 | CN¥2.84 Billion | +11.15% |
| 2022-12-31 | CN¥2.56 Billion | +35.19% |
| 2021-12-31 | CN¥1.89 Billion | +11.24% |
| 2020-12-31 | CN¥1.70 Billion | +194.51% |
| 2019-12-31 | CN¥577.80 Million | +29.12% |
| 2018-12-31 | CN¥447.50 Million | +31.35% |
| 2017-12-31 | CN¥340.69 Million | +38.36% |
| 2016-12-31 | CN¥246.23 Million | +37.87% |
| 2015-12-31 | CN¥178.59 Million | +18.71% |
| 2014-12-31 | CN¥150.45 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Yunnan Jianzhijia Health-Chain Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 29844.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.20 Billion | 42.93% |
| Common Stock | CN¥156.66 Million | 5.60% |
| Other Comprehensive Income | CN¥121.95K | 0.00% |
| Other Components | CN¥1.44 Billion | 51.46% |
| Total Equity | CN¥2.80 Billion | 100.00% |
Yunnan Jianzhijia Health-Chain Co Ltd Competitors by Market Cap
The table below lists competitors of Yunnan Jianzhijia Health-Chain Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Datawalk SA
WAR:DAT
|
$193.14 Million |
|
Rackspace Technology Inc
NASDAQ:RXT
|
$193.15 Million |
|
Backblaze Inc
NASDAQ:BLZE
|
$193.20 Million |
|
Tongqinglou Dining Co Ltd
SHG:605108
|
$193.25 Million |
|
Pure Cycle Corporation
NASDAQ:PCYO
|
$193.03 Million |
|
Sky Gold Limited
NSE:SKYGOLD
|
$193.03 Million |
|
CONCURRENT TECH. LS-01
F:FJV
|
$192.98 Million |
|
John Mattson Fastighetsföretagen AB (publ)
F:AR5
|
$192.97 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Yunnan Jianzhijia Health-Chain Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,861,130,202 to 2,797,247,891, a change of -63,882,311 (-2.2%).
- Net income of 128,126,430 contributed positively to equity growth.
- Dividend payments of 241,856,008 reduced retained earnings.
- Share repurchases of 53,998,221 reduced equity.
- Other comprehensive income increased equity by 121,948.
- Other factors increased equity by 103,723,540.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥128.13 Million | +4.58% |
| Dividends Paid | CN¥241.86 Million | -8.65% |
| Share Repurchases | CN¥54.00 Million | -1.93% |
| Other Comprehensive Income | CN¥121.95K | +0.0% |
| Other Changes | CN¥103.72 Million | +3.71% |
| Total Change | CN¥- | -2.23% |
Book Value vs Market Value Analysis
This analysis compares Yunnan Jianzhijia Health-Chain Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.11x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 11.14x to 1.11x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | CN¥1.81 | CN¥20.18 | x |
| 2015-12-31 | CN¥2.12 | CN¥20.18 | x |
| 2016-12-31 | CN¥2.93 | CN¥20.18 | x |
| 2017-12-31 | CN¥4.02 | CN¥20.18 | x |
| 2018-12-31 | CN¥5.26 | CN¥20.18 | x |
| 2019-12-31 | CN¥5.08 | CN¥20.18 | x |
| 2020-12-31 | CN¥14.75 | CN¥20.18 | x |
| 2021-12-31 | CN¥16.40 | CN¥20.18 | x |
| 2022-12-31 | CN¥20.56 | CN¥20.18 | x |
| 2023-12-31 | CN¥18.50 | CN¥20.18 | x |
| 2024-12-31 | CN¥18.12 | CN¥20.18 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Yunnan Jianzhijia Health-Chain Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.58%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.38%
- • Asset Turnover: 0.87x
- • Equity Multiplier: 3.80x
- Recent ROE (4.58%) is below the historical average (17.89%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 11.05% | 1.04% | 1.65x | 6.42x | CN¥1.65 Million |
| 2015 | 9.64% | 0.97% | 1.77x | 5.60x | CN¥-668.32K |
| 2016 | 27.69% | 3.45% | 1.77x | 4.54x | CN¥45.29 Million |
| 2017 | 26.94% | 4.04% | 1.58x | 4.23x | CN¥59.57 Million |
| 2018 | 29.08% | 4.83% | 1.64x | 3.68x | CN¥87.67 Million |
| 2019 | 28.42% | 4.76% | 1.77x | 3.37x | CN¥108.96 Million |
| 2020 | 14.63% | 5.62% | 1.29x | 2.02x | CN¥79.43 Million |
| 2021 | 15.74% | 5.74% | 1.00x | 2.73x | CN¥109.55 Million |
| 2022 | 14.53% | 4.98% | 0.80x | 3.64x | CN¥116.71 Million |
| 2023 | 14.48% | 4.56% | 0.91x | 3.48x | CN¥128.30 Million |
| 2024 | 4.58% | 1.38% | 0.87x | 3.80x | CN¥-151.60 Million |
Industry Comparison
This section compares Yunnan Jianzhijia Health-Chain Co Ltd's net assets metrics with peer companies in the Pharmaceutical Retailers industry.
Industry Context
- Industry: Pharmaceutical Retailers
- Average net assets among peers: $2,051,499,572
- Average return on equity (ROE) among peers: 9.14%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Yunnan Jianzhijia Health-Chain Co Ltd (605266) | CN¥2.62 Billion | 11.05% | 2.71x | $193.12 Million |
| Cachet Pharmaceutical Co Ltd (002462) | $4.92 Billion | 13.40% | 1.65x | $437.62 Million |
| Yunnan Hongxiang Yixintang (002727) | $497.43 Million | 20.70% | 1.22x | $545.21 Million |
| Luyan Pharma Co Ltd (002788) | $746.00 Million | 15.21% | 3.60x | $450.11 Million |
| Ji Yao Holding Group Co Ltd (300108) | $-366.31 Million | 0.00% | 0.00x | $18.23 Million |
| Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. (300937) | $856.04 Million | 6.95% | 0.97x | $170.91 Million |
| ShuYu Civilian Pharmacy Corp. Ltd. (301017) | $2.27 Billion | 10.12% | 2.47x | $188.58 Million |
| Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd (301126) | $1.78 Billion | 1.93% | 1.96x | $174.48 Million |
| Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A (301408) | $1.98 Billion | 5.80% | 1.33x | $323.73 Million |
| Shanghai No1 Pharmacy Co Ltd (600833) | $736.00 Million | 6.25% | 0.61x | $180.65 Million |
| Laobaixing Pharmacy (603883) | $7.10 Billion | 11.06% | 2.01x | $739.96 Million |